Gennova’s mRNA-based COVID-19 vaccine gets approval for Phase 2/3 clinical trials
The Hindu
The study will be conducted in the country at approximately 10-15 sites in Phase 2 and 22-27 sites in Phase 3.
India’s first mRNA-based COVID-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for Phase 2/3 clinical trails, the Department of Biotechnology (DBT) said on Tuesday. The Pune-based biotechnology company had submitted the interim clinical data of the vaccine’s Phase 1 study to the Central Drugs Standard Control Organisation (CDSCO), it said. The Vaccine Subject Expert Committee (SEC) reviewed the interim Phase 1 data and found that the HGCO19 vaccine was safe, tolerable, and immunogenic in the participants of the study.More Related News

NPCIL is to blame for storage of radioactive waste on site of Kudankulam nuclear power plant: Appavu
Tamil Nadu Speaker Appavu criticizes NPCIL for unsafe nuclear waste storage at Kudankulam, urging better solutions for public safety.












